Ken Griffin Arcturus Therapeutics Holdings Inc. Transaction History

Citadel Advisors LLC

$618 Billion
Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 22,200 shares of ARCT stock, worth $161,394. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,200

Previous 67,600 67.16%

Holding current value

$161,394

Previous $879,000 53.47%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$11.39 - $22.17 $153,081 - $297,964	13,440 Added 46.86%	42,120 $776,000
Q2 2025 Aug 14, 2025	BUY	$8.91 - $14.41 $199,022 - $321,876	22,337 Added 352.15%	28,680 $373,000
Q1 2025 May 15, 2025	SELL	$10.59 - $20.83 $77,667 - $152,767	-7,334 Reduced 53.62%	6,343 $67,000
Q4 2024 Feb 14, 2025	SELL	$14.82 - $25.48 $921,463 - $1.58 Million	-62,177 Reduced 81.97%	13,677 $232,000
Q3 2024 Nov 14, 2024	BUY	$18.08 - $25.38 $980,333 - $1.38 Million	54,222 Added 250.66%	75,854 $1.76 Million

Q2 2024 Aug 14, 2024	SELL	$24.35 - $44.39 $3.54 Million - $6.46 Million	-145,462 Reduced 87.05%	21,632 $526,000
Q1 2024 May 15, 2024	BUY	$31.23 - $42.99 $5.21 Million - $7.17 Million	166,727 Added 45429.7%	167,094 $5.64 Million
Q4 2023 Feb 14, 2024	SELL	$17.71 - $32.97 $2.61 Million - $4.86 Million	-147,506 Reduced 99.75%	367 $11,000
Q3 2023 Nov 14, 2023	BUY	$25.44 - $37.35 $660,473 - $969,680	25,962 Added 21.3%	147,873 $3.78 Million
Q2 2023 Aug 14, 2023	SELL	$23.94 - $32.36 $4.62 Million - $6.24 Million	-192,878 Reduced 61.27%	121,911 $3.5 Million
Q1 2023 May 15, 2023	BUY	$14.72 - $23.97 $169,029 - $275,247	11,483 Added 3.79%	314,789 $7.55 Million
Q4 2022 Feb 14, 2023	BUY	$14.14 - $23.06 $1.6 Million - $2.6 Million	112,903 Added 59.3%	303,306 $5.14 Million
Q3 2022 Nov 14, 2022	BUY	$13.05 - $22.13 $1.66 Million - $2.81 Million	126,867 Added 199.68%	190,403 $2.82 Million
Q2 2022 Aug 15, 2022	SELL	$12.26 - $31.17 $418,029 - $1.06 Million	-34,097 Reduced 34.92%	63,536 $1 Million
Q1 2022 May 16, 2022	BUY	$17.64 - $39.57 $1.45 Million - $3.26 Million	82,316 Added 537.42%	97,633 $2.63 Million
Q4 2021 Feb 14, 2022	SELL	$34.2 - $47.56 $1.93 Million - $2.68 Million	-56,420 Reduced 78.65%	15,317 $566,000
Q3 2021 Nov 15, 2021	SELL	$27.88 - $58.25 $3.31 Million - $6.92 Million	-118,884 Reduced 62.37%	71,737 $3.43 Million
Q1 2021 May 17, 2021	BUY	$38.75 - $86.92 $5.9 Million - $13.2 Million	152,371 Added 398.36%	190,621 $7.87 Million
Q4 2020 Feb 16, 2021	SELL	$34.61 - $123.66 $9.41 Million - $33.6 Million	-271,999 Reduced 87.67%	38,250 $1.66 Million
Q3 2020 Nov 16, 2020	SELL	$37.49 - $63.19 $14.5 Million - $24.5 Million	-388,035 Reduced 55.57%	310,249 $13.3 Million
Q2 2020 Aug 14, 2020	BUY	$12.66 - $58.27 $8.65 Million - $39.8 Million	683,546 Added 4637.98%	698,284 $32.6 Million
Q1 2020 May 15, 2020	BUY	$9.31 - $18.26 $16,804 - $32,959	1,805 Added 13.96%	14,738 $200,000
Q4 2019 Feb 14, 2020	BUY	$8.93 - $12.41 $115,491 - $160,498	12,933 New	12,933 $141,000

Others Institutions Holding ARCT

# of Institutions

173

Shares Held

26M

Call Options Held

2.32M

Put Options Held

866K

View Full List

About Arcturus Therapeutics Holdings Inc.

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $193M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

More about ARCT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account